Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

Purpose: Cytochrome P450 (CYP450) enzymes metabolize selective serotonin reuptake inhibitor (SSRI) drugs used in treatment of depression. Variants in these genes may impact treatment efficacy and tolerability. The purpose of this study was 2-fold: to systematically review the literature for evidence supporting CYP450 genotyping to guide SSRI treatment for major depression, and, where evidence is inadequate, to suggest future research.Methods: We searched MEDLINE® and other databases for studies addressing five key questions suggested by the Evaluation of Genomic Applications in Practice and Prevention Working Group. Eligibility criteria were defined, and studies were reviewed independently by paired researchers. A conceptual model was developed to guide future research.Results: Review of 1200 abstracts led to the final inclusion of 37 articles. The evidence indicates relatively high analytic sensitivity and specificity of tests detecting a subset of polymorphisms of CYP2D6, 2C19, 2C8, 2C9, and 1A1. We found marginal evidence regarding a clinical association between CYP450 variants and SSRI metabolism, efficacy, and tolerability in the treatment of depression.Conclusions: Current evidence does not support the use of CYP450 genotyping to guide SSRI treatment of patients with depression. Studies are proposed that will effectively guide decision-making in the area of CYP450 testing in depression, and genetic testing more generally.

[1]  A. Serretti,et al.  Pharmacogenetic studies in depression: a proposal for methodologic guidelines , 2008, The Pharmacogenomics Journal.

[2]  W. Koch,et al.  CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing , 2006, The Pharmacogenomics Journal.

[3]  M. Okawa,et al.  The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  Francis J McMahon,et al.  Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. , 2006, American journal of human genetics.

[5]  J. de Leon,et al.  AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry , 2006, Expert review of molecular diagnostics.

[6]  T. Someya,et al.  Polymorphisms in the 5-Hydroxytryptamine 2A Receptor and CytochromeP4502D6 Genes Synergistically Predict Fluvoxamine-Induced Side Effects in Japanese Depressed Patients , 2006, Neuropsychopharmacology.

[7]  M. Raggi,et al.  Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. , 2006, Current drug metabolism.

[8]  Seung-Hwan Lee,et al.  No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population , 2005, Psychiatric genetics.

[9]  E. Perucca,et al.  Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. , 2005, Basic & clinical pharmacology & toxicology.

[10]  M. Ingelman-Sundberg,et al.  Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.

[11]  A. Alderborn,et al.  Determination of CYP2D6 gene copy number by pyrosequencing. , 2005, Clinical chemistry.

[12]  R. Obach,et al.  SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDY , 2005, Drug Metabolism and Disposition.

[13]  A. Serretti,et al.  Pharmacogenetics in the treatment of depression: pharmacodynamic studies , 2005, Pharmacogenetics and genomics.

[14]  L. Teh,et al.  A simple multiplex PCR method for the concurrent detection of three CYP2C8 variants. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[15]  T. Someya,et al.  Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine , 2004, European Journal of Clinical Pharmacology.

[16]  J. Knowles,et al.  Investigation of serotonin-related genes in antidepressant response , 2004, Molecular Psychiatry.

[17]  V. Steen,et al.  Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. , 2004, The Journal of clinical psychiatry.

[18]  C. Nemeroff,et al.  Prediction of Antidepressant Response to Milnacipran by Norepinephrine Transporter Gene Polymorphisms , 2004 .

[19]  Cristina Cusin,et al.  Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[20]  Matthias J. Müller,et al.  Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting , 2004, European Journal of Clinical Pharmacology.

[21]  N. Thuerauf,et al.  CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study , 2004, Clinical pharmacology and therapeutics.

[22]  P. Nelemans,et al.  Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review , 2004, Molecular Psychiatry.

[23]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[24]  T. B. Üstün,et al.  Global burden of depressive disorders in the year 2000 , 2004, British Journal of Psychiatry.

[25]  R. Berecz,et al.  Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions , 2004, European Journal of Clinical Pharmacology.

[26]  P. Joyce,et al.  No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline , 2004, Human psychopharmacology.

[27]  M. Eichelbaum,et al.  CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real‐rime PCR , 2003, Human mutation.

[28]  M. Ansseau,et al.  Polymorphisms in the CYP 2D6 Gene: Association with Plasma Concentrations of Fluoxetine and Paroxetine , 2003, Therapeutic drug monitoring.

[29]  Zhaoqian Liu,et al.  Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[30]  A. Schatzberg,et al.  Pharmacogenetics of antidepressant medication intolerance. , 2003, The American journal of psychiatry.

[31]  D. Stryer,et al.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.

[32]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[33]  I. Reid,et al.  Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[34]  K. Otani,et al.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients , 2003, Psychopharmacology.

[35]  H. Shibuya,et al.  CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects , 2003, European Journal of Clinical Pharmacology.

[36]  A. Alderborn,et al.  Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. , 2002, Assay and drug development technologies.

[37]  A. Hoeft,et al.  Rapid and reliable method for cytochrome P450 2D6 genotyping. , 2002, Clinical chemistry.

[38]  Shunqing Xu,et al.  Detection of CYP I A1 polymorphisms with a colorimetric method based on mismatch hybridization. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[39]  T. J. Wilkinson,et al.  Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia , 2002, Human psychopharmacology.

[40]  B. Aizenstein,et al.  Characterization of cytochrome P450 2D6 alleles using the Invader system. , 2002, BioTechniques.

[41]  Bradford Ld.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[42]  C. Cusin,et al.  Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity , 2001, Molecular Psychiatry.

[43]  H. Zhou,et al.  Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. , 2001, British journal of clinical pharmacology.

[44]  Zhaoqian Liu,et al.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[45]  C. Allgulander,et al.  A prospective study of 86 new patients with social anxiety disorder , 2001, Acta psychiatrica Scandinavica.

[46]  C. Eap,et al.  Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers , 2001, Journal of clinical psychopharmacology.

[47]  A. Cravchik,et al.  Neurochemical individuality: genetic diversity among human dopamine and serotonin receptors and transporters. , 2000, Archives of general psychiatry.

[48]  D. Kupfer,et al.  Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression , 2000, Neuropsychopharmacology.

[49]  S. Ekins,et al.  (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[50]  M. Hersberger,et al.  Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. , 2000, Clinical chemistry.

[51]  D. Flockhart,et al.  Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects , 2000, Clinical pharmacology and therapeutics.

[52]  B. Carroll,et al.  Serotonin transporter gene polymorphism and antidepressant response , 2000, Neuroreport.

[53]  O. Olesen,et al.  Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes , 1999, Pharmacology.

[54]  C. Naranjo,et al.  Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. , 1999, Journal of clinical psychopharmacology.

[55]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[56]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[57]  D. Greenblatt,et al.  Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.

[58]  J. Amsterdam,et al.  Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. , 1997, The American journal of psychiatry.

[59]  R. Blouin,et al.  The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry , 1996, Clinical pharmacology and therapeutics.

[60]  F. Song,et al.  Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. , 1993, BMJ.

[61]  H. Schlake,et al.  Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline , 1992, Acta psychiatrica Scandinavica.

[62]  J. Hallas,et al.  The relationship between paroxetine and the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[63]  C. Bye,et al.  Paroxetine plasma levels: lack of correlation with efficacy or adverse events , 1989, Acta psychiatrica Scandinavica. Supplementum.

[64]  M. Garvey,et al.  Serum Fluoxetine and Norfluoxetine Concentrations and Antidepressant Response , 1989, Therapeutic drug monitoring.

[65]  A. Durand,et al.  Citalopram--a highly selective 5-HT uptake inhibitor--in the treatment of depressed patients. , 1987, International clinical psychopharmacology.

[66]  L. Flyckt,et al.  Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram , 1985, European Journal of Clinical Pharmacology.

[67]  P. L. Mikkelsen,et al.  Paroxetine in the treatment of depression ‐ a randomized comparison with amitriptyline , 1985, Acta psychiatrica Scandinavica.

[68]  C. Read,et al.  Encyclopedia of Statistical Sciences, Vol. 4. Icing the Tails-Limit Theorems. , 1985 .

[69]  N. L. Johnson,et al.  Encyclopedia of Statistical Sciences 2. , 1984 .

[70]  D. Goldstein,et al.  Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). , 2007, Evidence report/technology assessment.

[71]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[72]  加藤 正樹,et al.  Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism , 2006 .

[73]  T. Forst,et al.  Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. , 2004, Clinical laboratory.

[74]  A. Serretti,et al.  The pharmacogenomics of selective serotonin reuptake inhibitors , 2004, The Pharmacogenomics Journal.

[75]  K. Brøsen.  Some aspects of genetic polymorphism in the biotransformation of antidepressants. , 2004, Therapie.

[76]  L. Bertilsson,et al.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study , 2003, European Journal of Clinical Pharmacology.

[77]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[78]  J. Markowitz,et al.  Background information and treatment recommendations for patients with HIV/AIDS , 2000 .

[79]  Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. , 2000, The American journal of psychiatry.

[80]  T. Jobe,et al.  Possible therapeutic window for serotonin reuptake inhibitors. , 1994, The Journal of clinical psychiatry.

[81]  J. Cain,et al.  Possible therapeutic window for serotonin reuptake inhibitors [4] , 1994 .

[82]  J. Cain.  Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? , 1992, The Journal of clinical psychiatry.

[83]  C. Beasley,et al.  Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. , 1990, Psychopharmacology bulletin.

[84]  Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. , 1990, Journal of affective disorders.

[85]  N. Fineberg,et al.  Plasma‐Level Response Relationships with Fluoxetine and Zimelidine , 1990, Clinical neuropharmacology.